News coverage about Inogen (NASDAQ:INGN) has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inogen earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the medical technology company an impact score of 45.3912974772241 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Inogen (NASDAQ INGN) opened at $115.59 on Friday. Inogen has a twelve month low of $62.69 and a twelve month high of $130.05. The stock has a market capitalization of $2,403.64, a PE ratio of 93.98, a P/E/G ratio of 3.90 and a beta of 1.13.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The firm had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same quarter last year, the company posted $0.25 earnings per share. The business’s revenue was up 26.8% on a year-over-year basis. analysts anticipate that Inogen will post 1.19 earnings per share for the current fiscal year.
INGN has been the topic of a number of research reports. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a report on Thursday, November 9th. Needham & Company LLC raised their price target on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Leerink Swann reissued an “outperform” rating and set a $120.00 price target (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, BidaskClub lowered Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Inogen currently has a consensus rating of “Hold” and a consensus target price of $102.71.
In other Inogen news, Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total value of $119,060.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $119,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $112.35, for a total value of $280,875.00. The disclosure for this sale can be found here. Insiders sold a total of 81,500 shares of company stock worth $9,267,695 in the last ninety days. 5.31% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2018/01/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-inogen-ingn-share-price.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.